{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:51:06Z","timestamp":1790524266525,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lublin DS22\/22"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Opioids are used to treat pain, but despite their effectiveness, they possess several side effects such as respiratory depression, tolerance and physical dependence. Cebranopadol has been evaluated as a solution to this problem. The compound acts on the mu opioid receptor and the nociceptin\/orphanin receptor and these receptors co-activation can reduce opioid side-effects without compromising analgesia. In the present review, we have compiled information on the effects of cebranopadol, its pharmacokinetics, and clinical trials involving cebranopadol, to further explore its promise in pain management.<\/jats:p>","DOI":"10.3390\/molecules27133987","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T04:12:01Z","timestamp":1655871121000},"page":"3987","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cebranopadol as a Novel Promising Agent for the Treatment of Pain"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4980-3926","authenticated-orcid":false,"given":"Wojciech","family":"Ziemichod","sequence":"first","affiliation":[{"name":"Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Doktora Witolda Chod\u017aki Street, 20-400 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4178-1515","authenticated-orcid":false,"given":"Jolanta","family":"Kotlinska","sequence":"additional","affiliation":[{"name":"Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Doktora Witolda Chod\u017aki Street, 20-400 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-0633","authenticated-orcid":false,"given":"Ewa","family":"Gibula-Tarlowska","sequence":"additional","affiliation":[{"name":"Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Doktora Witolda Chod\u017aki Street, 20-400 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Karkoszka","sequence":"additional","affiliation":[{"name":"Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Doktora Witolda Chod\u017aki Street, 20-400 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Kedzierska","sequence":"additional","affiliation":[{"name":"Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Doktora Witolda Chod\u017aki Street, 20-400 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"ref_1","unstructured":"Jab\u0142o\u0144ski, P., Bukowska, B., and Czaba\u0142a, J.C.Z. (2012). Zespo\u0142y uzale\u017cnie\u0144 od substancji psychoaktywnych. Uzale\u017cnienie od narkotyk\u00f3w: Podre\u0328cznik dla terapeut\u00f3w, Krajowe Biuro ds, Przeciwdzia\u0142ania Narkomanii."},{"key":"ref_2","first-page":"27252","article-title":"A Review of Potential Adverse Effects of Long-Term Opioid Therapy: A Practitioner\u2019s Guide","volume":"14","author":"Baldini","year":"2012","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_3","first-page":"191","article-title":"Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nature reviews","volume":"6","author":"Crofford","year":"2010","journal-title":"Rheumatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1126\/science.6541807","article-title":"Separation of morphine analgesia from physical dependence","volume":"226","author":"Ling","year":"1984","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0301-0082(02)00008-4","article-title":"Exploring the opioid system by gene knockout","volume":"66","author":"Kieffer","year":"2002","journal-title":"Prog. Neurobiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/FBP.0b013e32834a1f2c","article-title":"Delta opioid receptor analgesia: Recent contributions from pharmacology and molecular approaches","volume":"22","author":"Kieffer","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pharmthera.2013.06.003","article-title":"Delta opioid receptors in brain function and diseases","volume":"140","author":"Kieffer","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.amjmed.2010.01.014","article-title":"Pain\/Depression dyad: A key to a better understanding and treatment of functional somatic syndromes","volume":"123","author":"Goldenberg","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/aps.2010.164","article-title":"Effects of ATPM-ET, a novel \u03ba agonist with partial \u03bc activity, on physical dependence and behavior sensitization in mice","volume":"31","author":"Sun","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/jpet.114.213694","article-title":"Cebranopadol: A novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist","volume":"349","author":"Linz","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.270.5237.792","article-title":"A neuropeptide that activates an opioidlike G protein-coupled receptor","volume":"270","author":"Reinscheid","year":"1995","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.bjp.0703219","article-title":"Pharmacology of nociceptin and its receptor: A novel therapeutic target","volume":"129","author":"Guerrini","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8666","DOI":"10.1073\/pnas.93.16.8666","article-title":"Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene","volume":"93","author":"Mollerau","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.pbb.2006.11.014","article-title":"Cholecystokinin is necessary for the expression of morphine conditioned place preference","volume":"85","author":"Mitchell","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_15","first-page":"1368","article-title":"Effects of CCK-8 and its receptor antagonists given intracerebroventricularly on withdrawal symptom of morphine dependent rats","volume":"27","author":"Wen","year":"2011","journal-title":"Chin. Pharmacol. Bull."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1358\/mf.1998.20.8.487502","article-title":"The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats","volume":"20","author":"Crespi","year":"1998","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0741-8329(96)00179-6","article-title":"Spontaneous preference for ethanol in naive rats is influenced by cholecystokinin A receptor antagonism","volume":"14","author":"Crespi","year":"1997","journal-title":"Alcohol"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Dourish, C.T., Cooper, S.J., Iversen, S.D., and Iversen, L.L. (1992). CCK receptors and anxiety in rats. Multiple Cholecystokinin Receptors in the CNS, Oxford University Press.","DOI":"10.1093\/oso\/9780198577560.001.0001"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1530-0277.1993.tb00797.x","article-title":"Cholecystokinin and bombesin inhibit ethanol and food intake in rats selectively bred for ethanol sensitivity","volume":"17","author":"Kulkosky","year":"1993","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jpain.2008.11.006","article-title":"Antinociceptive effects of nociceptin\/orphanin FQ administered intrathecally in monkeys","volume":"10","author":"Ko","year":"2009","journal-title":"J. Pain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.bjp.0704279","article-title":"Orphanin FQ\/nociception attenuates the development of morphine tolerance in rats","volume":"134","author":"Lutfy","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0014-2999(94)00688-4","article-title":"A selective CCK-B receptor antagonist potentiates mu-, but not delta-opioid receptor-mediated antinociception in the formalin test","volume":"273","author":"Noble","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e00247","DOI":"10.1002\/prp2.247","article-title":"Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin\/orphanin FQ and opioid receptor agonist","volume":"4","author":"Rizzi","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/bja\/aeu332","article-title":"Cebranopadol: A first in-class example of a nociceptin\/orphanin FQ receptor and opioid receptor agonist","volume":"114","author":"Lambert","year":"2015","journal-title":"Br. J. Anaesth."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40262-017-0545-1","article-title":"Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic","volume":"57","author":"Kleideiter","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/jvp.12948","article-title":"Cebranopadol, a novel first-in-class drug candidate: Method validation and first exploratory pharmacokinetic study in rabbits","volume":"44","author":"Gajda","year":"2021","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1073\/pnas.87.18.7105","article-title":"PD134308, a selective antagonist of cholecystokinin type-B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes","volume":"87","author":"Xu","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(93)90948-H","article-title":"Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of m-opioid analgesia by CCKB receptor antagonist L365,260 in rat spinal cord","volume":"234","author":"Zhou","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrd2572","article-title":"The nociceptin\/orphanin FQ receptor: A target with broad therapeutic potential","volume":"7","author":"Lambert","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/377532a0","article-title":"Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor","volume":"377","author":"Meunier","year":"1995","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/adb.12550","article-title":"Limited potential of cebranopadol to produce opioid-type physical dependence in rodents","volume":"23","author":"Tzschentke","year":"2018","journal-title":"Addict. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/FBP.0000000000000420","article-title":"Inhibition of experimental visceral pain in rodents by cebranopadol","volume":"30","author":"Schiene","year":"2019","journal-title":"Behav. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejphar.2018.05.005","article-title":"Nociceptin\/orphanin FQ opioid peptide (NOP) receptor and \u00b5-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain","volume":"832","author":"Schiene","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10787-017-0405-5","article-title":"Evaluation of cebranopadol, a dually acting nociceptin\/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemo-therapy-induced neuro-pathic pain","volume":"26","year":"2018","journal-title":"Inflammo-Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/j.pain.0000000000000986","article-title":"Cebranopadol, a novel first-in-class analgesic drug candidate: First experience in patients with chronic low back pain in a randomized clinical trial","volume":"158","author":"Christoph","year":"2017","journal-title":"Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ejp.1331","article-title":"Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, dou-ble-blind, noninferiority trial","volume":"23","author":"Eerdekens","year":"2019","journal-title":"Eur. J. Pain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.peptides.2018.12.001","article-title":"NOP agonist action of cebranopadol counteracts its liability to promote physical dependence","volume":"112","author":"Ruzza","year":"2019","journal-title":"Peptides"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/jpet.117.241042","article-title":"Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats","volume":"362","author":"Matzeu","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fpsyt.2017.00234","article-title":"Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors","volume":"8","author":"Shen","year":"2017","journal-title":"Front. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9254","DOI":"10.1038\/s41598-020-66250-z","article-title":"Effects of Cebranopadol on Cocaine-induced Hyperactivity and Cocaine Pharmacokinetics in Rats","volume":"10","author":"Wei","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpainsymman.2019.05.012","article-title":"Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience with Cancer-Related Pain for up to 26 Weeks","volume":"58","author":"Koch","year":"2019","journal-title":"J. Pain Symptom Manag."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/13\/3987\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:36:46Z","timestamp":1760139406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/13\/3987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":41,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["molecules27133987"],"URL":"https:\/\/doi.org\/10.3390\/molecules27133987","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]}}}